Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With The End Of Pfizergan, Pfizer Has To Grow It Alone

This article was originally published in The Pink Sheet Daily

Executive Summary

Investors are wondering what Pfizer might do next – and especially whether or not it will split – after the company is outmaneuvered by the US government and ends its ambition to merge with Allergan.

You may also be interested in...



Death And Tax Inversion: Policy Fight Won't Go Away, Now Spawning Lawsuits

US Chamber of Commerce wants court to eliminate IRS rule that blocked Pfizer's acquisition of Allergan; AbbVie hit with second suit over its 2014 proposed acquisition of Shire.

Pfizer Oncology Strategy: An Investment Starts To Pay Off

With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.

Pfizer’s Biosimilar Strategy Might Be Working

Pfizer's biosimilar franchise  is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS079386

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel